{"id":"hoe140-icatibant","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bradykinin is a potent inflammatory peptide that increases vascular permeability and causes swelling. By competitively blocking the B2 receptor on endothelial and smooth muscle cells, icatibant prevents bradykinin-induced vasodilation and plasma extravasation. This mechanism is particularly relevant in hereditary angioedema (HAE), where dysregulation of the contact system leads to excessive bradykinin production.","oneSentence":"Icatibant is a selective bradykinin B2 receptor antagonist that blocks the inflammatory effects of bradykinin, a key mediator of angioedema.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:16.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE) acute attack treatment"},{"name":"Angioedema prevention in HAE patients"}]},"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT06346899","phase":"","title":"A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-07-20","conditions":"Hereditary Angioedema (HAE)","enrollment":115},{"nctId":"NCT07009262","phase":"","title":"A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks","status":"COMPLETED","sponsor":"KalVista Pharmaceuticals, Ltd.","startDate":"2025-04-21","conditions":"Hereditary Angioedema","enrollment":88},{"nctId":"NCT07290855","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema","status":"COMPLETED","sponsor":"Nang Kuang Pharmaceutical Co., Ltd.","startDate":"2024-09-27","conditions":"Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE)","enrollment":5},{"nctId":"NCT05509569","phase":"","title":"A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Hereditary Angioedema (HAE)","enrollment":32},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04057131","phase":"","title":"FIRAZYR General Drug Use-Results Survey (Japan)","status":"COMPLETED","sponsor":"Shire","startDate":"2018-11-20","conditions":"Hereditary Angioedema (HAE)","enrollment":179},{"nctId":"NCT06587464","phase":"","title":"A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-10-16","conditions":"Hereditary Angioedema (HAE)","enrollment":19},{"nctId":"NCT05834777","phase":"PHASE3","title":"Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-11","conditions":"Intradialytic Hypotension","enrollment":26},{"nctId":"NCT01034969","phase":"","title":"Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-10","conditions":"Hereditary Angioedema (HAE)","enrollment":1761},{"nctId":"NCT05489640","phase":"","title":"A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-11-18","conditions":"Hereditary Angioedema (HAE)","enrollment":85},{"nctId":"NCT05407597","phase":"PHASE2, PHASE3","title":"Inhibition of Bradykinin in COVID-19 Infection With Icatibant","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2022-05-16","conditions":"SARS CoV 2 Infection","enrollment":32},{"nctId":"NCT05010876","phase":"PHASE2","title":"Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).","status":"COMPLETED","sponsor":"GCS Ramsay Santé pour l'Enseignement et la Recherche","startDate":"2021-02-04","conditions":"Covid19","enrollment":44},{"nctId":"NCT04978051","phase":"PHASE2","title":"Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection","status":"COMPLETED","sponsor":"Sebastian Videla","startDate":"2021-04-12","conditions":"COVID-19 Pneumonia","enrollment":73},{"nctId":"NCT04654351","phase":"PHASE3","title":"A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-01-15","conditions":"Hereditary Angioedema","enrollment":2},{"nctId":"NCT00997204","phase":"PHASE3","title":"EASSI - Evaluation of the Safety of Self-Administration With Icatibant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-09-25","conditions":"Hereditary Angioedema","enrollment":151},{"nctId":"NCT00912093","phase":"PHASE3","title":"A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-16","conditions":"Hereditary Angioedema","enrollment":98},{"nctId":"NCT00500656","phase":"PHASE3","title":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)","status":"COMPLETED","sponsor":"Shire","startDate":"2005-03-01","conditions":"Hereditary Angioedema","enrollment":85},{"nctId":"NCT00097695","phase":"PHASE3","title":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2004-12-28","conditions":"Angioedema","enrollment":84},{"nctId":"NCT01919801","phase":"PHASE3","title":"Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2013-12-02","conditions":"Angiotensin Converting Enzyme Inhibitor Induced Angioedema","enrollment":118},{"nctId":"NCT01386658","phase":"PHASE3","title":"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2012-01-27","conditions":"Hereditary Angioedema (HAE)","enrollment":32},{"nctId":"NCT03888755","phase":"PHASE3","title":"A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants","status":"COMPLETED","sponsor":"Shire","startDate":"2015-03-18","conditions":"Hereditary Angioedema (HAE)","enrollment":8},{"nctId":"NCT02045264","phase":"PHASE1","title":"Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2014-02-21","conditions":"Hereditary Angioedema (HAE)","enrollment":12},{"nctId":"NCT03177798","phase":"PHASE2","title":"Mitochondria and Chronic Kidney Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-08-01","conditions":"Hemodialysis-Induced Symptom, Mitochondrial Diseases","enrollment":11},{"nctId":"NCT03005184","phase":"PHASE2","title":"Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2017-09","conditions":"Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III","enrollment":""},{"nctId":"NCT01574248","phase":"PHASE4","title":"Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2011-08","conditions":"ACE Inhibitor-associated Angioedema","enrollment":33},{"nctId":"NCT01457430","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-12","conditions":"Hereditary Angioedema","enrollment":19},{"nctId":"NCT00517582","phase":"PHASE1","title":"Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2007-09","conditions":"Angioneurotic Edema","enrollment":13},{"nctId":"NCT00223704","phase":"PHASE2, PHASE3","title":"Bradykinin Receptor Antagonism During Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2006-05","conditions":"Cardiopulmonary Bypass, Inflammation, Fibrinolysis","enrollment":150},{"nctId":"NCT00303056","phase":"PHASE2","title":"Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Joint Disease","enrollment":590},{"nctId":"NCT01154361","phase":"PHASE2","title":"AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"","conditions":"Angioedema","enrollment":""},{"nctId":"NCT00965120","phase":"NA","title":"The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2009-08","conditions":"Ischaemic Heart Diseases","enrollment":12},{"nctId":"NCT00965393","phase":"NA","title":"The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2009-08","conditions":"Ischaemic Heart Diseases","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HOE140 Icatibant","genericName":"HOE140 Icatibant","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icatibant is a selective bradykinin B2 receptor antagonist that blocks the inflammatory effects of bradykinin, a key mediator of angioedema. Used for Hereditary angioedema (HAE) acute attack treatment, Angioedema prevention in HAE patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}